Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2011 (2011), Article ID 150450, 6 pages
http://dx.doi.org/10.1155/2011/150450
Review Article

Gaucher Disease and Cancer: Concept and Controversy

1Department of Biology, Centre for Biomedical Research, University of Victoria, P.O. Box 3020, Station CSC, Victoria, BC, Canada V8W 3N5
2TNC Scientific Consulting, Calgary, AB, Canada

Received 27 January 2011; Revised 2 April 2011; Accepted 15 April 2011

Academic Editor: Anton M. Jetten

Copyright © 2011 Francis Y. M. Choy and Tessa N. Campbell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Harmanci and Y. Bayraktar, “Gaucher disease: new developments in treatment and etiology,” World Journal of Gastroenterology, vol. 14, no. 25, pp. 3968–3973, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Beutler and G. A. Grabowski, “Gaucher disease,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. L. Beaudet, and W. S. Sly, Eds., pp. 3635–3668, McGraw-Hill, New York, NY, USA, 2001. View at Google Scholar
  3. M. Fuller, “Sphingolipids: the nexus between Gaucher disease and insulin resistance,” Lipids in Health and Disease, vol. 9, p. 113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Wafaei and F. Y. Choy, “Glucocerebrosidase recombinant allele: molecular evolution of the glucocerebrosidase gene and pseudogene in primates,” Blood Cells, Molecules, and Diseases, vol. 35, no. 2, pp. 277–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Y. Choy, W. Zhang, H. P. Shi et al., “Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles,” Blood Cells, Molecules, and Diseases, vol. 38, no. 3, pp. 287–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. S. Hruska, M. E. LaMarca, C. R. Scott, and E. Sidransky, “Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA),” Human Mutation, vol. 29, no. 5, pp. 567–583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. de Fost, J. M. Aerts, and C. E. Hollak, “Gaucher disease: from fundamental research to effective therapeutic interventions,” Netherlands Journal of Medicine, vol. 61, no. 1, pp. 3–8, 2003. View at Google Scholar · View at Scopus
  8. D. Elstein and A. Zimran, “Review of the safety and efficacy of imiglucerase treatment of Gaucher disease,” Journal of Biologics, vol. 3, pp. 407–417, 2009. View at Google Scholar · View at Scopus
  9. J. M. F. G. Aerts, M. Yasothan, and P. Kirkpatrick, “Velglucerase alfa,” Nature Reviews Drug Discovery, vol. 9, no. 1, pp. 837–838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Zimran, G. Altarescu, M. Phillips et al., “Phase 1/II ansd extension study of velaglucerse alfa (Gene-Activated Human Glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48 months experience,” Blood, vol. 115, pp. 4651–4656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Aviezer, E. Almen-Brill, Y. Shaaltiel, R. Chertkoff, S. Hashmueli, and A. Zimran, “Novel enzyme replacement therapy for Gaucher disease: Phase III pivotal clinical trial with plant cell expressed recombinant glucocerebrosidase (prGCD)-taliglucerase alfa,” in Proceedings of the 6th Annual WORLD Symposium, Miami, Fla, USA, 2010. View at Publisher · View at Google Scholar
  12. T. N. Campbell and F. Y. M. Choy, “Knockdown of chimeric glucocerebrosidase by green fluorescent protein-directed small interfering RNA,” Genetics and Molecular Research, vol. 3, no. 2, pp. 282–287, 2004. View at Google Scholar · View at Scopus
  13. T. M. Cox, “Gaucher disease: clinical profile and therapeutic developments,” Journal of Biologics, vol. 4, pp. 299–313, 2010. View at Google Scholar · View at Scopus
  14. E. Lukina, N. Watman, E. A. Arreguin et al., “Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study,” Blood, vol. 116, pp. 4095–4098, 2010. View at Google Scholar · View at Scopus
  15. J. Pinkhas, M. Djaldetti, and M. Yaron, “Coincidence of multiple myeloma with Gaucher's disease,” Israel Journal of Medical Sciences, vol. 1, no. 4, pp. 537–540, 1965. View at Google Scholar · View at Scopus
  16. P. W. Pratt, S. Kochwa, and S. Estren, “Immunoglobulin abnormalities in Gaucher's disease. Report of 16 cases,” Blood, vol. 31, no. 5, pp. 633–640, 1968. View at Google Scholar · View at Scopus
  17. D. Benjamin, H. Joshua, M. Djaldetti, B. Hazaz, and J. Pinkhas, “Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher's disease,” Scandinavian Journal of Haematology, vol. 22, no. 2, pp. 179–184, 1979. View at Google Scholar · View at Scopus
  18. P. C. Ruestow, D. J. Levinson, R. Catchatourian, S. Sreekanth, H. Cohen, and S. Rosenfeld, “Coexistence of IgA myeloma and Gaucher's disease,” Archives of Internal Medicine, vol. 140, pp. 1115–1116, 1980. View at Google Scholar · View at Scopus
  19. D. Garfinkel, Y. Sidi, M. Ben-Bassat, F. Salomonm, B. Hazaz, and J. Pinkhaus, “Coexistence of Gaucher's disease and multiple myeloma,” Archives of Internal Medicine, vol. 142, pp. 2229–2230, 1982. View at Google Scholar · View at Scopus
  20. R. Gal, S. Gukovsky-Oren, S. Floru, M. Djaldetti, and E. Kessler, “Sequential appearance of breast carcinoma, multiple myeloma and Gaucher's disease,” Haematologica, vol. 73, no. 1, pp. 63–65, 1988. View at Google Scholar · View at Scopus
  21. Y. Liel, M. J. Hausmann, and M. Mozes, “Case report: serendipitous Gaucher's disease presenting as elevated erythrocyte sedimentation rate due to monoclonal gammopathy,” American Journal of the Medical Sciences, vol. 301, no. 6, pp. 393–394, 1991. View at Google Scholar · View at Scopus
  22. A. Shiran, B. Brenner, A. Laor, and I. Tatarsky, “Increased risk of cancer in patients with Gaucher disease,” Cancer, vol. 72, no. 1, pp. 219–224, 1993. View at Google Scholar · View at Scopus
  23. L. Shvidel, N. Hurwitz, M. Shtalrid, S. Zur, O. Oliver, and A. Berrebi, “Complex IgA gammopathy in Gaucher's disease,” Leukemia and Lymphoma, vol. 20, no. 1-2, pp. 165–168, 1995. View at Google Scholar · View at Scopus
  24. K. Brady, L. Corash, and V. Bhargava, “Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease,” Archives of Pathology and Laboratory Medicine, vol. 121, no. 10, pp. 1108–1111, 1997. View at Google Scholar · View at Scopus
  25. H. Harder, J. Eucker, C. Zang et al., “Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria,” Annals of Hematology, vol. 79, no. 11, pp. 640–643, 2000. View at Google Scholar · View at Scopus
  26. F. Mateja, J. Malý, M. Tichý, and F. Langr, “Uncommon combination of multiple myeloma in three patients,” Vnitrni lekarstvi, vol. 46, no. 7, pp. 413–417, 2000. View at Google Scholar · View at Scopus
  27. B. E. Rosenbloom, N. J. Weinreb, A. Zimran, K. A. Kacena, J. Charrow, and E. Ward, “Gaucher disease and cancer incidence: a study from the Gaucher Registry,” Blood, vol. 105, no. 12, pp. 4569–4572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. De Fost, S. Vom Dahl, G. J. Weverling et al., “Increased incidence of cancer in adult Gaucher disease in Western Europe,” Blood Cells, Molecules, and Diseases, vol. 36, no. 1, pp. 53–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. H. Taddei, K. A. Kacena, M. Yang et al., “The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients,” American Journal of Hematology, vol. 84, no. 4, pp. 208–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Lo, P. Stein, S. Mullaly et al., “Expanding spectrum of the association between type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types—correlation with genotype and phenotype,” American Journal of Hematology, vol. 85, no. 5, pp. 340–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Chang Lo, L. T. Yam, A. I. Rubenstone, and S. O. Schwartz, “Gaucher's disease associated with chronic lymphocytic leukaemia, gout and carcinoma,” Journal of Pathology, vol. 116, no. 4, pp. 203–207, 1975. View at Google Scholar · View at Scopus
  32. T. Mark, C. Dominguez, and A. M. Rywlin, “Gaucher's disease associated with chronic lymphocytic leukemia,” Southern Medical Journal, vol. 75, no. 3, pp. 361–363, 1982. View at Google Scholar · View at Scopus
  33. H. Fox, P. McCarthy, J. Andre-Schwartz, Y. Shoenfeld, and K. B. Miller, “Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and B-cell proliferations?” Cancer, vol. 54, no. 2, pp. 312–314, 1984. View at Google Scholar · View at Scopus
  34. S. Kaufman, V. Rosenfeld, R. Yona, and M. Varon, “Gaucher's disease associated with chronic lymphocytic leukaemia,” Clinical and Laboratory Haematology, vol. 8, no. 4, pp. 321–324, 1986. View at Google Scholar · View at Scopus
  35. E. Shinar, Z. L. Gershon, R. Leiserowitz, Y. Matzner, S. Yatziv, and A. Polliack, “Coexistence of Gaucher Disease and Philadelphia positive chronic granulocytic leukemia,” American Journal of Hematology, vol. 12, no. 2, pp. 199–202, 1982. View at Google Scholar · View at Scopus
  36. P. E. Petrides, P. LeCoutre, J. Müller-Höcker et al., “Coincidence of Gaucher's disease due to a private mutation and Ph' positive chronic myeloid leukemia,” American Journal of Hematology, vol. 59, no. 1, pp. 87–90, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Krause, C. Bures, and R. E. Lee, “Acute leukaemia and Gaucher's disease,” Scandinavian Journal of Haematology, vol. 23, no. 2, pp. 115–118, 1979. View at Google Scholar · View at Scopus
  38. G. M. Corbett, P. J. Darbyshire, G. T. Besley, and A. C. Parker, “Adult Gaucher disease in association with acute leukaemia,” Postgraduate Medical Journal, vol. 63, no. 744, pp. 899–900, 1987. View at Google Scholar · View at Scopus
  39. A. Ranade, S. Selegean, G. Sandhu, V. Ghali, and V. P. Shan, “Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy,” American Journal of Hematology, vol. 85, no. 11, pp. 908–909, 2010. View at Google Scholar · View at Scopus
  40. J. D. Brody, R. Advani, L. K. Shin, D. B. Bingham, and S. A. Rosenberg, “Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges,” Annals of Hematology, vol. 85, no. 11, pp. 817–820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Sanchez, J. Etzell, G. Kim, S. Packman, C. Fairley, and R. Goldsby, “Pediatric malignancies: case 2. Peripheral T-cell lymphoma in an adolescent with unsuspected Gaucher disease,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4792–4793, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. L. R. Sharer, J. A. Barondess, R. T. Silver, and G. F. Gray, “Association of Hodgkin disease and Gaucher disease,” Archives of Pathology and Laboratory Medicine, vol. 98, no. 6, pp. 376–378, 1974. View at Google Scholar · View at Scopus
  43. S. Y. Cho and M. Sastre, “Coexistence of Hodgkin's disease and Gaucher's disease,” American Journal of Clinical Pathology, vol. 65, no. 1, pp. 103–108, 1976. View at Google Scholar · View at Scopus
  44. A. H. Bruckstein, A. Karanas, and J. J. Dire, “Gaucher's disease associated with Hodgkin's disease,” American Journal of Medicine, vol. 68, no. 4, pp. 610–613, 1980. View at Google Scholar · View at Scopus
  45. J. C. Lyons, B. W. Scheithauer, and W. W. Ginsburg, “Gaucher's disease and glioblastoma multiforme in two siblings. A clinicopathologic study,” Journal of Neuropathology and Experimental Neurology, vol. 41, no. 1, pp. 45–53, 1982. View at Google Scholar · View at Scopus
  46. S. H. Tsung and E. Cotes, “Coexistence of bronchogenic carcinoma and Gaucher disease,” Archives of Pathology and Laboratory Medicine, vol. 101, no. 1, p. 56, 1977. View at Google Scholar · View at Scopus
  47. J. P. Leone and A. Z. Dudek, “Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer,” Anticancer Research, vol. 28, no. 6B, pp. 3937–3939, 2008. View at Google Scholar · View at Scopus
  48. M. Kojiro, M. Kage, H. Abe, M. Imamura, K. Shiraishi, and M. Mizoguchi, “Association of dysgerminoma and Gaucher's disease,” Cancer, vol. 51, no. 4, pp. 712–715, 1983. View at Google Scholar · View at Scopus
  49. Z. Erjavec, C. E. Hollak, and E. G. De Vries, “Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy,” Annals of Oncology, vol. 10, no. 2, p. 243, 1999. View at Google Scholar · View at Scopus
  50. R. Xu, P. Mistry, G. Mckenna et al., “Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature,” Seminars in Liver Disease, vol. 25, no. 2, pp. 226–229, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Wantanabe, M. Yanagisawa, S. Sonobe, J. Matsumoto, and H. Miura, “An adult form of Gaucher's disease with a huge tumour formation of the right tibia,” International Orthopaedics, vol. 8, no. 3, pp. 195–202, 1984. View at Publisher · View at Google Scholar · View at Scopus
  52. M. R. Pins, H. J. Mankin, R. J. Xavier, D. I. Rosenthal, G. R. Dickersin, and A. E. Rosenberg, “Malignant epithelioid hemangioendothelioma of the tibia associated with a bone infarct in a patient who had Gaucher disease. A case report,” Journal of Bone and Joint Surgery, vol. 77, no. 5, pp. 777–781, 1995. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Bhm, W. Kunz, H. P. Horny, and H. Einsele, “Adult Gaucher disease in association with primary malignant bone tumors,” Cancer, vol. 91, no. 3, pp. 457–462, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Zver, M. Bracko, and D. Andoljsek, “Primary bone angiosarcoma in a patient with Gaucher disease,” International Journal of Hematology, vol. 92, no. 2, pp. 374–377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Costello, T. O'Callaghan, and G. Sébahoun, “Gaucher disease and multiple myeloma,” Leukemia and Lymphoma, vol. 47, no. 7, pp. 1365–1368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Shoenfeld, L. A. Gallant, M. Shaklai, E. Livni, M. Djaldetti, and J. Pinkhas, “Gaucher's disease: a disease with chronic stimulation of the immune system,” Archives of Pathology and Laboratory Medicine, vol. 106, no. 8, pp. 388–391, 1982. View at Google Scholar · View at Scopus
  57. D. A. Hughes, “Enzyme, substrate, and myeloma in Gaucher disease,” American Journal of Hematology, vol. 84, no. 4, pp. 199–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Michelakakis, C. Spanou, A. Kondyli et al., “Plasma tumor necrosis factor-α (TNF-α) levels in the Gaucher disease,” Biochimica et Biophysica Acta, vol. 1317, no. 3, pp. 219–222, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. M. J. Allen, B. J. Myer, A. M. Khokher, N. Rushton, and T. M. Cox, “Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10,” QJM, vol. 90, no. 1, pp. 19–25, 1997. View at Google Scholar · View at Scopus
  60. C. E. Hollak, L. Evers, J. M. Aerts, and M. H. Van Oers, “Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease,” Blood Cells, Molecules and Diseases, vol. 23, no. 2, pp. 201–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Barak, M. Acker, B. Nisman et al., “Cytokines in Gaucher's disease,” European Cytokine Network, vol. 10, no. 2, pp. 205–210, 1999. View at Google Scholar · View at Scopus
  62. M. de Fost, T. A. Out, F. A. de Wilde et al., “Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature,” Annals of Hematology, vol. 87, no. 6, pp. 439–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. P. M. Campeau, M. Rafei, M. N. Boivin, Y. Sun, G. A. Grabowski, and J. Galipeau, “Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome,” Blood, vol. 114, no. 15, pp. 3181–3190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. S. H. Dikman, M. Goldstein, T. Kahn, M. Leon, and N. J. Weinreb, “Amyloidosis: an unusual complication of Gaucher's disease,” Archives of Pathology and Laboratory Medicine, vol. 102, no. 9, pp. 460–462, 1978. View at Google Scholar · View at Scopus
  65. S. M. Hanash, D. L. Rucknagel, K. P. Heidelberger, and N. S. Radin, “Primary amyloidosis associated with Gaucher's disease,” Annals of Internal Medicine, vol. 89, no. 5 I, pp. 639–641, 1978. View at Google Scholar · View at Scopus
  66. A. Kaloterakis, A. Filiotou, J. Koskinas et al., “Systemic A.L. amyloidosis in Gaucher disease: a case report and review of the literature,” Journal of Internal Medicine, vol. 246, no. 6, pp. 587–590, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Burstein, V. Zakuth, G. Rechavi, and Z. Spirer, “Abnormalities of cellular immunity and natural killer cells in Gaucher's disease,” Journal of Clinical and Laboratory Immunology, vol. 23, no. 3, pp. 149–151, 1987. View at Google Scholar · View at Scopus
  68. L. A. Boven, M. Van Meurs, R. G. Boot et al., “Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages,” American Journal of Clinical Pathology, vol. 122, no. 3, pp. 359–369, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Balreira, L. Lacerda, C. S. Miranda, and F. A. Arosa, “Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model,” British Journal of Haematology, vol. 12, no. 5, pp. 667–676, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. P. K. Mistry, J. Liu, M. Yang et al., “Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 19473–19478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Ron and M. Horowitz, “ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity,” Human Molecular Genetics, vol. 14, no. 16, pp. 2387–2398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. J. DePaolo, O. Goker-Alpan, T. Samaddar, G. Lopez, and E. Sidransky, “The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism,” Movement Disorders, vol. 24, no. 11, pp. 1571–1578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. P. K. Mistry, N. J. Weinreb, R. O. Brady, and G. A. Grabowski, “Gaucher disease: resetting the clinical and scientific agenda,” American Journal of Hematology, vol. 84, no. 4, pp. 205–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Zimran, I. Liphshitz, M. Barchana, A. Abrahamov, and D. Elstein, “Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic,” Blood Cells, Molecules, and Diseases, vol. 34, no. 3, pp. 197–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. O. Landgren, I. Turesson, G. Gridley, and N. E. Caporaso, “Risk of malignant disease among 1525 adult male US veterans with Gaucher disease,” Archives of Internal Medicine, vol. 167, no. 11, pp. 1189–1194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. N. J. Weinreb, H. C. Andersson, M. Banikazemi et al., “Prevalence of type 1 Gaucher disease in the United States,” Archives of Internal Medicine, vol. 168, no. 3, pp. 326–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. B. E. Rosenbloom, P. Becker, and N. Weinreb, “Multiple myeloma and Gaucher genes,” Genetics in Medicine, vol. 11, no. 2, p. 134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Zimran, Y. Ilan, and D. Elstein, “Enzyme replacement therapy for mild patients with Gaucher disease,” American Journal of Hematology, vol. 84, no. 4, pp. 202–204, 2009. View at Publisher · View at Google Scholar
  79. J. Mitsui, I. Mizuta, A. Toyoda et al., “Mutations for Gaucher disease confer high susceptibility to Parkinson disease,” Archives of Neurology, vol. 66, no. 5, pp. 571–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Ron, D. Rapaport, and M. Horowitz, “Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease,” Human Molecular Genetics, vol. 19, no. 19, pp. 3771–3781, 2010. View at Google Scholar · View at Scopus
  81. Y. H. Xu, B. Quinn, D. Witte, and G. A. Grabowski, “Viable mouse models of acid β-glucosidase deficiency: the defect in Gaucher disease,” American Journal of Pathology, vol. 163, no. 5, pp. 2093–2101, 2003. View at Google Scholar · View at Scopus
  82. G. B. Sinclair, G. Jevon, K. E. Colobong, D. R. Randall, F. Y. M. Choy, and L. A. Clarke, “Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease,” Molecular Genetics and Metabolism, vol. 90, no. 2, pp. 148–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. I. H. Park, N. Arora, H. Huo et al., “Disease-specific induced pluripotent stem cells,” Cell, vol. 134, no. 5, pp. 877–886, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Sun, B. Liou, H. Ran et al., “Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits,” Human Molecular Genetics, vol. 19, no. 6, pp. 1088–1097, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. H. Xu, L. Jia, B. Quinn et al., “Global gene expression profile progression in Gaucher disease mouse models,” BMC Genomics, vol. 1, no. 1, article 20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Hughes, M. D. Cappellini, M. Berger et al., “Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease,” British Journal of Haematology, vol. 138, no. 6, pp. 676–686, 2007. View at Publisher · View at Google Scholar · View at Scopus